TuHURA Biosciences (HURA) Cash from Operations (2010 - 2026)
TuHURA Biosciences (HURA) posted quarterly Cash from Operations of 4412953.0 for Q1 2026, up 6.87% year-over-year from 4129321.42 in Q1 2025, and up 20.19% quarter-over-quarter from 5529150.0 in Q4 2025.
TuHURA Biosciences (HURA) Cash from Operations (2010 - 2026) Analysis & Trends
TuHURA Biosciences' Cash from Operations history runs 17 years deep, the most recent figure standing at 4412953.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 6.87% year-over-year to 4412953.0; the TTM figure through Mar 2026 stood at 27303681.0 (up 13.32% YoY), while the FY2025 annual figure was 27629150.0, down 87.59% from the prior year.
- Cash from Operations for Q1 2026 stood at 4412953.0, up from 5529150.0 in the prior quarter.
- The five-year high for Cash from Operations was 3535000.0 in Q2 2023, with the low at 12128521.0 in Q3 2024.
- The 5-year median for Cash from Operations is 5529150.0 (2025), against an average of 5376845.13.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations jumped 79.32% in 2023, then slumped 820.92% in 2024.
- TuHURA Biosciences' Cash from Operations stood at 7213000.0 in 2022, then jumped by 52.39% to 3434000.0 in 2023, then tumbled by 253.19% to 12128521.0 in 2024, then soared by 54.41% to 5529150.0 in 2025, then grew by 20.19% to 4412953.0 in 2026.
- Business Quant data shows HURA's Cash from Operations at 4412953.0 in Q1 2026, 5529150.0 in Q4 2025, and 11113416.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | -8.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.41 Mn |
| Mar 31, 2026 | -4.41 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -11.11 Mn |
| Sep 30, 2025 | -11.11 Mn |
| Jun 30, 2025 | -6.25 Mn |
| Jun 30, 2025 | -6.25 Mn |
| Mar 31, 2025 | -4.74 Mn |
| Mar 31, 2025 | -4.74 Mn |
| Sep 30, 2024 | -12.13 Mn |
| Sep 30, 2024 | -12.13 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | -5.73 Mn |
| Mar 31, 2024 | -5.73 Mn |
| Dec 31, 2023 | -3.43 Mn |
| Dec 31, 2023 | -3.43 Mn |
| Sep 30, 2023 | -1.32 Mn |
| Sep 30, 2023 | -1.32 Mn |